Sun Pharma shares ends flat; firm gets USFDA nod for BromSite

Sun Pharma stock price rose by nearly 2 per cent on Monday as the pharma major received approval from the US health regulator USFDA for its non-steroid drug BromSite used to treat inflammation and prevent pain in patients undergoing cataract surgery.

The stock gained 1.74 per cent to Rs 825.95 on BSE but ended flat.

On NSE, it went up by 1.75 per cent to Rs 826.

One of the company's wholly-owned subsidiaries "has received approval from USFDA for its New Drug Application (NDA) related to BromSite (bromfenac ophthalmic solution) 0.075 per cent for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery," Sun Pharmaceutical Industries said in a filing to BSE.

The drug has been developed by InSite Vision which the company had acquired in November 2015, it added.

The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016, it said.